Invega sustenna

Manufactured by Johnson & Johnson

Sourced in China

Invega Sustenna is a long-acting injectable antipsychotic medication used to treat schizophrenia in adults. It contains the active ingredient paliperidone palmitate, which is a derivative of risperidone. Invega Sustenna is administered by a healthcare professional through an intramuscular injection, typically once every 4 weeks.

Automatically generated - may contain errors

Lab products found in correlation

Invega trinza, by Johnson & Johnson (2 mentions) Tetrahydrofuran, by Thermo Fisher Scientific (1 mentions) Acetonitrile, by Thermo Fisher Scientific (1 mentions) Methanol, by Thermo Fisher Scientific (1 mentions) Citric acid, by Sinopharm (1 mentions) Risperdal consta, by Johnson & Johnson (1 mentions)

3 protocols using invega sustenna

Formulation and Characterization of Invega Sustenna

Check if the same lab product or an alternative is used in the 5 most similar protocols

Invega Sustenna^® (reference formulation, KFB5Y00) was obtained from Janssen Pharmaceutica N.V. Tween 20 and Poly(ethylenglycol) 4000 (PEG4000) were provided by Nanjing Well Pharmaceutical Co., Ltd. (Nanjing, China). Sodium dihydrogen phosphate and dibasic sodium phosphate were supplied by Chengdu Huayi Pharmaceutical Accessories Manufacturing Co., Ltd. (Chengdu, China). Citric acid was purchased from Sinopharm Chemical Reagent Co., Ltd. (Shanghai, China). Sodium hydroxide was obtained from Sichuan Jinshan Pharmaceutical Co., Ltd. (Meishan, China). Diazepam was purchased from Shandong Xinyi Pharmaceutical Co., Ltd. (Dezhou, China). Methanol, acetonitrile, N, N-dimethylformamide, and tetrahydrofuran of chromatographic grade were purchased from Fisher Scientific (Pittsburgh, PA, USA).

Shi J., Wang D., Tian Y., Wang Z., Gao J., Liu N., Gao X., Zheng A., Zhang H, & Xiang M. (2022). Comparison of Paliperidone Palmitate from Different Crystallization Processes and Effect on Formulations In Vitro and In Vivo. Pharmaceutics, 14(5), 1094.

+ Open protocol

+ Expand

Survey of LAIA Medication Adherence

Check if the same lab product or an alternative is used in the 5 most similar protocols

Administering pharmacists were asked to invite all adults receiving aripiprazole (Abilify Maintena; Otsuka America Pharmaceutical), paliperidone palmitate (Invega Sustenna, Invega Trinza; Janssen Pharmaceuticals), and risperidone (Risperdal Consta; Janssen Pharmaceuticals) at a participating pharmacy to complete the survey. Participants were included if they were 18 years of age or older. Participants who were younger than 18 years, those who received LAIAs other than the LAIAs listed in the inclusion criteria, and those who declined to complete survey were excluded from the study. Over the course of 8 weeks, 716 surveys were faxed to administering pharmacists. The administering pharmacist provided a paper copy of the faxed survey to the participants interested in taking part in the study after LAIA administration.

Mooney E.V., Hamper J.G., Willis R.T., Farinha T.L, & Ricchetti C.A. (2018). Evaluating patient satisfaction with pharmacist-administered long-acting injectable antipsychotics in the community pharmacy. Journal of the American Pharmacists Association : JAPhA, 58(4S).

+ Open protocol

+ Expand

Schizophrenia Patients' Enrollment Criteria

Check if the same lab product or an alternative is used in the 5 most similar protocols

Details of the inclusion/exclusion criteria for the DREaM study have been previously described.^{9 (link)} Briefly, the study enrolled adult men and women aged 18-35 years who had a current diagnosis of schizophrenia or schizophreniform disorder and a first psychotic episode within the past 24 months. Patients were excluded if they met the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria for a moderate or severe substance use disorder (with the exception of nicotine) within 2 months of screening. The present analysis only included patients with a diagnosis of schizophrenia, as that is the US Food and Drug Administration-approved indication for 1-month or 3-month PP extended-release injectable suspension (Invega Sustenna and Invega Trinza, respectively; Janssen Pharmaceuticals, Inc).^{11 ,12} All study participants provided written informed consent.

Basu A., Benson C., Turkoz I., Patel C., Baker P, & Brown B. (2022). Health care resource utilization and costs in patients receiving long-acting injectable vs oral antipsychotics: A comparative analysis from the Disease Recovery Evaluation and Modification (DREaM) study. Journal of Managed Care & Specialty Pharmacy, 28(10), 10.18553/jmcp.2022.28.10.1086.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!